Abatacept therapy and safety management - 25/06/09
, Pascal Claudepierre 2, Arnaud Constantin 3, Bruno Fautrel 4, Laure Gossec 5, Jacques-Éric Gottenberg 6, Philippe Goupille 7, Éric Hachulla 8, Charles Masson 9, Jacques Morel 10, Alain Saraux 11, Thierry Schaeverbeke 12, Daniel Wendling 13, Xavier Mariette 14, Jean Sibilia 15
Corresponding author. Tel.: +33 4 91 38 34 62; fax: +33 4 91 38 38 87.Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 53 |
| Iconographies | 0 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Objectives |
To elaborate a how-to-use abatacept material intended to help physicians in the management of patients with inflammatory diseases treated with this drug in routine practice.
Methods |
1) Selection of the relevant domains by a rheumatologists’ panel; 2) Search for published evidence in each domain; 3) Elaboration of the clinical tool guide with a 3-level gradation of evidence (evidence-based medicine EBM, official recommendations and expert’s opinion). The experts were 11 academic rheumatologists with a large experience in prescribing abatacept and in managing rheumatoid arthritis. They were all members of the CRI (Club Rhumatismes et Inflammation), a section of the French Rheumatology Society dedicated to the inflammatory rheumatic diseases. Each fact sheet was reviewed by two other experts; 4) Regular updating based on medical literature and postmarketing surveillance data.
Results |
Four domains were considered relevant: abatacept contraindications, management of side effects or associated diseases appearing during abatacept treatment, management of “practical situations” such as surgery or pregnancy, physician and patient information.
After the literature analysis and discussion during an experts’ meeting, a consensus was reached on:
– | a pre-treatment checklist aimed at searching abatacept contraindications; |
– | a what-to-do document when facing side effects or associated diseases (autoimmune pathology, bacterial or viral infections, cardiovascular diseases, intolerance to abatacept, solid or haematological malignancy) or “practical situations” (surgery, pregnancy, vaccination, travel, drug-drug interactions); |
– | an example of standard information letter to be addressed to the attending physician (rheumatologist and general practitioner); |
– | an example of standard information letter to be addressed to the patient. |
Conclusion |
Based on both an EBM approach and an expert’s opinion approach, this abatacept clinical tool guide should provide assistance to all physicians attending patients treated with abatacept. For a better implementation in clinical practice, this tool guide will be available online at www.cri-net.com/ and regularly updated.
Le texte complet de cet article est disponible en PDF.Keywords : Abatacept, Monitoring, Safety, Health services
Plan
Vol 76 - N° S1
P. S3-S55 - mai 2009 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?